Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10306181 | 1.00 | KMT2A (0.44) | KMT2AHSD11B1METAP2ALDH1A1HPGD | |
| SCHEMBL12167676 | 0.86 | KMT2A (0.42) | KMT2AHSD11B1METAP2ALDH1A1HPGD | |
| SCHEMBL12167710 | 0.86 | KMT2A (0.42) | KMT2AHSD11B1METAP2ALDH1A1HPGD | |
| SCHEMBL12436350 | 0.86 | KMT2A (0.47) | KMT2AHSD11B1METAP2ALDH1A1HPGD | |
| SCHEMBL3981420 | 0.84 | KMT2A (0.46) | KMT2AHSD11B1METAP2ALDH1A1KCNA5 | |
| SCHEMBL3978062 | 0.84 | KMT2A (0.46) | KMT2AHSD11B1METAP2ALDH1A1KCNA5 | |
| SCHEMBL4169655 | 0.84 | KMT2A (0.46) | KMT2AHSD11B1METAP2ALDH1A1KCNA5 | |
| SCHEMBL12167715 | 0.82 | KMT2A (0.39) | KMT2AHSD11B1METAP2ALDH1A1HPGD | |
| SCHEMBL12167681 | 0.82 | KMT2A (0.39) | KMT2AHSD11B1METAP2ALDH1A1HPGD | |
| SCHEMBL3977640 | 0.80 | KMT2A (0.44) | KMT2AHSD11B1METAP2KCNA5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8211910-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7563805-B2 | 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | AAAS, NPEPPS, TEAD4 | KMT2A 3317/4885HSD11B1 4381/4885METAP2 1462/4885 |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | KMT2A 3178/4885HSD11B1 4462/4885METAP2 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.